Document:

Document

Exhibit 10.19

SECOND AMENDMENT
TO LICENSE AND COLLABORATION AGREEMENT

This Second Amendment to License and Collaboration Agreement (the “Amendment”) is entered into effective as of the last date set forth on the signature page hereof (the “Amendment Effective Date”) by and between LEXICON PHARMACEUTICALS, INC., a Delaware corporation with its principal offices at 8800 Technology Forest Place, The Woodlands, Texas 77381 U.S.A. (“Lexicon”), and IPSEN PHARMA SAS, a French corporation with its principal offices at 65 Quai Georges Gorse, Boulogne-Billancourt 92100, France (“Ipsen”).

Capitalized terms not otherwise defined herein shall have the meaning given to such terms in the Collaboration Agreement.  Unless otherwise expressly stated herein, the Sections referred to herein refer to the Sections in the Collaboration Agreement.

        R E C I T A L S

        WHEREAS, Lexicon and Ipsen are parties to that certain License and Collaboration Agreement dated October 21, 2014, as amended March 17, 2015 (the “Collaboration Agreement”);

        WHEREAS, Lexicon and Ipsen desire to amend the Collaboration Agreement to reflect (a) the dissolution of the JDC and JCC and assumption of the JDC’s and JCC’s responsibilities by the JSC, (b) certain modifications to the JSC’s meeting schedule, (c) the elimination of the obligation of the Executive Officers of the Parties to meet once per year and (d) certain modifications to the Parties’ reporting obligations;

        NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, Lexicon and Ipsen hereby agree as follows:

        1. The JDC and JCC are hereby dissolved, with all responsibilities of the JDC set forth in Section 2.2(e) of the Collaboration Agreement and all responsibilities of the JCC set forth in Section 2.3(e) of the Collaboration Agreement being hereby assumed by the JSC and added to the JSC’s responsibilities set forth in Section 2.1(b) of the Collaboration Agreement.

        2. Section 2.1(h)(i) of the Collaboration Agreement is hereby amended so that, after the receipt of the first Marketing Authorization for a Licensed Product from the EMA (or from the applicable Regulatory Authority in the first Major EU Country), the JSC shall meet once per year rather than twice per year, at such time as may be agreed by the Parties.

        3. Section 2.4 of the Collaboration Agreement is hereby deleted in its entirety and shall have no further force or effect.

4. The third sentence in Section 5.1(a) is hereby amended to recite “Ipsen shall submit an updated Commercialization Plan for JSC review and approval at least fifteen (15) days prior to the annual meeting of the JSC during the Term.”

5. Section 6.2 of the Collaboration Agreement is hereby amended so that the written reports to be provided by each Party to the other Party following the first filing of an MAA with the EMA (or the applicable Regulatory Authority in the first Major EU Country) will be provided on an annual basis rather than within thirty (30) days after the end of each six (6) month period during each calendar year.  Such written reports shall set forth in reasonable detail such Party’s and its Affiliates’ and sublicensees’ (a) activities and progress during the preceding twelve (12) month period in carrying out the Commercialization Plan, including information concerning the preparations for commercial launch of the Licensed Products, First Commercial Sale, achievement of sales level event milestones and the territories in which the foregoing activities are conducted, such information to be provided separately for each Licensed Product, and (b) any planned commercialization activities in the next twelve (12) month period, including expected timelines.  Such written reports shall be provided by each Party to the other Party at least fifteen (15) days prior to the annual meeting of the JSC contemplated by Section 2.1(h)(i) of the Collaboration Agreement.

        6. This Amendment shall not amend or modify the covenants, terms, conditions, rights and obligations of the parties under the Collaboration Agreement, except as specifically set forth herein.  The Collaboration Agreement shall continue in full force and effect in accordance with its terms as amended by this Amendment.
        7. This Amendment may be executed in counterparts, each of which shall be deemed an original, but both of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the parties have caused their duly authorized representatives to execute and deliver this Amendment as of the Amendment Effective Date.

IPSEN PHARMA SAS

By:                                                                        
(Signature of Authorized Representative)

Printed Name:                                                      
Title:                                                                     
Date:                                                                     

LEXICON PHARMACEUTICALS, INC.

By:                                                                        
(Signature of Authorized Representative)

Printed Name:                                                      
Title:                                                                     
Date:                                                                     

-2-Exhibit 4.36

      

       

      

      
        BioLineRx Ltd.

         

        

        Compensation Policy for Executives 

        and Directors

        

        

        March 2020

      

      
        
          

      

      BioLineRx Compensation Policy for Executives and Directors

    

    

    

    Table of contents:

    

    

    
      	
              1.

            	
              Purpose and Background

            	
              3

            
	
              2.

            	
              Our Executive Compensation Policy

            	
              4

            
	

            	
              2.1.   Approvals and Inception

            	
              4

            
	

            	
              2.2.   Compensation Policy Targets

            	
              4

            
	

            	
              2.3.   Considerations in Defining Compensation Policy for Executives

            	
              4

            
	

            	
              2.4.   Factors to be Considered in the Establishment of the Policy

            	
              6

            
	

            	
              2.5.   Conditions Regarding Variable Components of Compensation

            	
              6

            
	

            	
              2.6.   Motivation and Retention

            	
              7

            
	
              3.

            	
              Corporate Governance

            	
              7

            
	

            	
              3.1.   Compensation Committee Membership and Duties

            	
              7

            
	

            	
              3.2.   Policy Confirmation, Amendment and Reaffirmation

            	
              8

            
	

            	
              3.3.   Approval Process

            	
              9

            
	
              4.

            	
              Compensation Model

            	
              10

            
	

            	
              4.1.   Framework

            	
              10

            
	

            	
              4.2.   Compensation Structure

            	
              10

            
	

            	
              4.3.   Summary of Recommended Compensation Structure

            	
              16

            
	

            	
              4.4.   Summary of Compensation Objectives

            	
              17

            
	
              5.

            	
              Compensation of Directors

            	
              17

            
	
              6.

            	
              Examination by Independent Auditors

            	
              18

            
	
              7.

            	
              Restitution in Case of Error

            	
              18

            
	
              8.

            	
              Responsibility for Communication of the Policy and Revisions thereto

            	
              18

            
	
              9.

            	
              Periodic Review of Executive Compensation

            	
              18

            

    

    

    

  

  
    
      

  

  
  
    BioLineRx Compensation Policy for Executives and Directors

    
      
         

        

        	
                 1.

              	
                Purposes and Background

              

      

    

     

    The purposes of this Compensation Policy for Executives and Directors (the “Policy”) of BioLineRx Ltd. (the “Company”) are to establish the Company’s compensation strategy for executive officers and
      directors and to provide guidelines for determining the compensation of its executive officers and directors.

    

    

    The Policy has been adopted in accordance with the requirements of Israel’s Companies Law, 1999-5759 (the “Companies Law”), as amended. The Policy applies to the compensation arrangements of the
      Company’s executive officers (individually, an “Executive” and collectively, the “Executives”) and directors. Executives and directors will be referred to collectively as “Office Holders.”

    

    

    BioLineRx is a clinical-stage, publicly-traded (NASDAQ/ TASE: BLRX) biopharmaceutical development company based in Modi’in, Israel. Our Company is dedicated
        to identifying, in-licensing and developing promising therapeutic candidates intended to satisfy an unmet medical need or provide advantages over current therapies. Our mission is to be leaders in Israel’s biopharmaceutical industry, to
      identify promising drug compounds and creatively drive the development process towards commercialization. Our ultimate goal is to improve global health through the creation of new therapeutics.

    

    

    This Policy is designed to promote the achievement of the Company’s goals and support the realization of its work plan and business strategy over the long term.

    
      3

      
        

    

    
      BioLineRx Compensation Policy for Executives and Directors

    

    

    

    
      
        	2.	
                Our Compensation Policy

              

      

    

     

    
      
        	

              	2.1.	
                Approvals and Inception

              

      

    

     

    

    This Policy was reviewed and approved by the Compensation Committee of the Board of Directors (the “Compensation Committee”) on February 25, 2016 and the Committee’s recommendations were presented to
      the Board of Directors (the “Board”). The Policy was approved by the Board on March 8, 2016 for a period of three years beginning from the date of approval of this Policy by the shareholders.

    

    

    
      
        	

              	2.2.	
                Compensation Policy Targets

              

      

    

     

    

    Our pay-for-performance approach drives us to set coherent standards for the mechanisms by which we establish compensation levels and payouts, as well as the
      results and behavior we aim to incentivize. All incentive systems at all Company levels are required to contribute to the sustainable growth of the Company by aligning individual goals and behavior with our common long-term strategy and mission.

    

    

    
      
        	

              	2.3.	
                Considerations in Defining Compensation Policy for Executives

              

      

    

     

    

    The following considerations were taken into account when establishing this Policy:

    

    

    
      
        	

              	•	
                Promotion of the Company’s long-term goals, its strategy and operating plan

              

      

    

     

    

    Compensation is considered performance-based to the extent that a direct link is maintained between variable compensation and performance and that rewards are consistent with long-term stakeholder
      value creation.

    

    

    The fixed components of compensation will be examined at least every two years and compared to the market. The Board may change the amount of the fixed components for one or more of the Executives
      after receiving a recommendation for such from the Compensation Committee. The change may be made if the Board concludes that such a change would promote the Company’s goals, operating plans and objectives and after taking into account the business
      and legal implications of the proposed change and its impact on labor relations at the Company. Any such changes are subject to formal approval by the relevant parties.

    

    

    As for the variable components of compensation, the types and amounts of such components will be determined with the purpose of creating the maximum consistency between this Policy and Company’s
      operating plan and objectives.

    
      4

      
        

    

    
      
        BioLineRx Compensation Policy for Executives and Directors

      

    

     

    
      
        	

              	•	
                Creation of appropriate incentives for the Executives, considering the risk management policy of the Company

              

      

    

     

    

    The Company will formulate a balanced total compensation structure of fixed and variable compensation elements, avoiding undue emphasis on variable compensation which may induce behavior not aligned
      with the Company’s tolerance for risk. Furthermore, when periodically examining this Policy, the Board and the Compensation Committee will discuss the reasonableness of compensation, while taking into account the risk management policy of the
      Company.

    

    

    
      
        	

              	•	
                Size of the Company and the nature of its activities

              

      

    

     

    

    We aim to adopt compensation practices capable of guaranteeing distinctive and effective compensation solutions that drive our overall business and personnel strategies in the best possible manner.

    

    

    Our periodic monitoring of market trends and awareness of international practices contribute to the sound formulation of competitive compensation, as well as transparency and internal fairness. We
      strive for a balance between creating incentives which support long-term company goals and retention targets. On the basis of periodic benchmarking, we aim to explore peer group ranges in compensation levels, pay mix and total reward structures for
      effective retention and motivation of our critical executive resources. .

    

    

    At the Company level, we analyze the overall compensation trends of the market in order to make informed decisions about our compensation approach. With specific reference to the Executives, we have
      used a benchmarking analysis based on an internally developed list of publicly traded companies that represent, as closely as possible, our peer group. The Compensation Committee arrived at this peer group of publicly traded companies by looking at
      numerous criteria as follows:

     

    

    
      
        	

              	•	
                Industry and sub-industry

                 

                

              

      

    

    
      
        	

              	•	
                Business scope and dimension

                 

                

              

      

    

    
      
        	

              	•	
                Market capitalization

                 

                

              

      

    

    
      
        	

              	•	
                Number of employees

                 

                

              

      

    

    
      
        	

              	•	
                Size and breadth of product offering

                 

                

              

      

    

    
      
        	

              	•	
                Unique professional skill sets required

                 

                

              

      

    

    
      
        	

              	•	
                Regulatory environment

                 

                

              

      

    

    
      
        	

              	•	
                Location

              

      

    

    

    

    
      5

      
        

    

    
      
        BioLineRx Compensation Policy for Executives and Directors

      

    

     

    

    At a personal level for each Executive, and as appropriate throughout the organization, benchmarking and trend analyses may be conducted considering other peer groups to assure competitive alignment
      with the relevant market.

    

    

    
      
        	

              	•	
                Variable components of compensation

              

      

    

     

    

    When considering variable components of compensation, the contribution of the Executive in fulfilling his or her specific corporate role and in achieving the Company’s short and long-term goals and
      the growth of its long-term profitability should be considered. The variable components in the compensation package will be based primarily on measurable parameters. Those parameters will be derived from the Company’s strategic plan.

    

    

    
      
        	

              	2.4.	
                Factors to be Considered in the Establishment of the Policy

                 

                

              

      

    

    
      
        	

              	•	
                Education, qualifications, expertise, professional experience and accomplishments of the Executive

                 

                

              

      

    

    
      
        	

              	•	
                Role and areas of responsibility of the Executive and previous salary agreements offered by the Company to the Executive

                 

                

              

      

    

    
      
        	

              	•	
                The ratio between the Executive’s compensation and the compensation of other Company employees, including outsourced personnel, especially in comparison to the average salary and median salary of other Company employees, as well as the
                  impact this ratio might have on the work relations within the Company

                 

                

              

      

    

    
      
        	

              	•	
                Where the compensation includes variable components - the possibility of decreasing such components, as well as establishing a maximum value for non-cash variable equity components.

                 

                

              

      

    

    
      
        	

              	•	
                When the compensation includes termination grants – the employment period of the officer, his/her employment terms during such period, the Company’s performance during such period, the Executive’s contribution to the achievement of
                  Company objectives and maximization of its profits, as well as the circumstances of the Executive’s termination. In no circumstances shall termination grants (including any notice periods) exceed a total of six monthly salaries

              

      

    

    

    

    
      
        	

              	2.5.	
                Conditions Regarding Variable Components of Compensation

              

      

    

     

    

    Variable components of compensation will be primarily based on measurable short- and long-term criteria. Nevertheless, the Company is allowed to base a non-material part of variable compensation on
      qualitative non-measurable criteria which focus on the Executive’s contribution to the Company.

    
      6

      
        

    

    
      
        
          BioLineRx Compensation Policy for Executives and Directors

        

      

    

    

    

    The Company will also establish a defined ratio between the variable and the fixed components of compensation, as well as a maximum amount for all variable components as of the date on which they are
      paid (or as of the grant date for non-cash variable equity components).

    

    

    The Company will also establish guidelines under which the Executive will refund to the Company part of the compensation received, if it was paid based on information that was retroactively restated
      in the financial reports of the Company.

    

    

    Minimal vesting or holding periods of variable equity components will be established in a manner that supports the appropriate long-term objectives of the Company.

      

    

    
      
        	

              	2.6.	
                Motivation and Retention

              

      

    

     

    

    We aim to attract, motivate and retain the best resources capable of achieving our Company mission and adhering to our Company values.

    

    

    Effective compensation strategies represent a key driver to positively reinforce employee commitment, engagement and alignment with the Company’s goals. Our total compensation approach provides for a
      balanced package of fixed and variable elements, each designed to impact in a specific manner the motivation and retention of employees.

    

    

    
      
        	3.	
                Corporate Governance

              

      

    

     

    
      
        	

              	3.1.	
                Compensation Committee Membership and Duties

              

      

    

     

      

    The Compensation Committee will be composed of at least three members of the Board. Each member of the Compensation Committee must meet the independence
        requirements established under applicable law. All of the Company’s external directors (as defined by the Companies Law) will be appointed as members of the Compensation Committee and will constitute a majority of the Committee’s members. The
        Chairperson of the Compensation Committee must be an external director.

    

    

    The Compensation Committee is responsible for advising the Board as to the Policy and its implementation. The Committee’s main duties are:

    

    

    
      
        	

              	•	
                Analyzing and monitoring market compensation trends, practices and pay levels

                  

                

              

      

    

    
      
        	

              	•	
                Making recommendations to the Board regarding a compensation policy for Office Holders

              

         

        

        
          7

          
            

        

      

    

    
      
        
          
            
              
                BioLineRx Compensation Policy for Executives and Directors

              

            

          

        

         

        

        	

              	•	
                Recommending an extension of the Policy to the Board at least once every three years (in cases where the Policy has been established for a period exceeding three years)

                 

                

              

      

    

    
      
        	

              	•	
                Advising the Board from time to time regarding the need to update the Policy

                  

                

              

      

    

    
      
        	

              	•	
                Monitoring the Company’s implementation of the Policy

                  

                

              

      

    

    
      
        	

              	•	
                Approving employment contracts of Executives that require approval of the Compensation Committee

                 

                

              

      

    

    
      
        	

              	•	
                Approving certain employment transactions and contracts which may be exempt from shareholder approval.

              

      

    

    

    

    The Committee acts in accordance with a charter approved by the Board in June 2013.

    

    

    
      
        	

              	3.2.	
                Policy Confirmation, Amendment and Reaffirmation

              

      

    

     

    

    The Board will review the Policy from time to time, but not less than once every three years, as well as the need to revise the Policy.

    

    

    Any amendment to the Policy requires specific approval as set forth in the Companies Law. The term of the Policy shall be for three years from the date of its approval by the shareholders. Following
      such three-year term, the Policy will again be brought to shareholders for approval by the required special majority. The Companies Law provides, however, that the Company’s Board of Directors may approve a compensation policy even if it was not
      approved by shareholders; provided that the Compensation Committee and thereafter the Board determine, based on detailed reasoning, and after having re-examined the compensation policy, that approval of the compensation policy, notwithstanding the
      rejection of the Company’s shareholders, will benefit the Company.

    
      8

      
        

    

    
      
        
          
            BioLineRx Compensation Policy for Executives and Directors

          

        

      

    

    

    

    
      
        	

              	3.3.	
                Approval Process

              

      

    

     

    

    Approval of CEO terms of employment:

    

    

    

     

    

    Approval of director/controlling shareholder terms of employment:

     

    
      9

      
        

    

    
      
        
          
            
              BioLineRx Compensation Policy for Executives and Directors

            

          

        

      

    

     

    

    Approval of Executive terms of employment (including deviation from the Compensation Policy):

     

    

     

    

     

    

     

    

     

    

    

    
      
        	4.	
                Compensation Model

              

      

    

     

    
      
        	

              	4.1.	
                Framework

              

      

    

     

    

    This Policy relates to all executive management and directors of the Company.

    

    

    
      
        	

              	4.2.	
                Compensation Structure for Executives

              

      

    

     

    

    The compensation package will be comprised of fixed and variable elements. Each element has a role to play in a balanced compensation package and recognizes different aspects of performance:

    

    

    
      
        	

              	•	
                Base Salary - paid for work performed for a specific role that requires a certain level of experience, skill, competence and responsibility

                 

                

              

      

    

    
      
        	

              	•	
                Benefits - to meet legal requirements and to promote the well-being and specific needs of employees for greater productivity and retention

                  

                

              

      

    

    
      
        	

              	•	
                Variable Components:

                 

                

              

      

    

    
      
        	

              	*	
                Short-Term Incentives (Annual Bonuses) - for achievement of yearly operating plan targets

                 

                

              

      

    

    
      
        	

              	*	
                Long-Term Incentives (Equity Compensation Plans) - for driving long-term sustainability, shareholder value creation and achievement of long-range goals

                 

                

              

      

    

    
      
        	

              	*	
                Special Bonus - in addition to the annual cash bonus, the Company may, from time to time, determine that an Executive shall be paid a special bonus, considering the special contribution of such
                  Executive to the Company, as well as and any other special circumstances

              

      

    

    

    

    
      10

      
        

    

    
      
        
          
            
              
                BioLineRx Compensation Policy for Executives and Directors

              

            

          

        

      

    

     

    

    Base Salary

     

    

    The fixed component of compensation is remuneration for the specific role of the Executive and the scope of his or her responsibilities. It also reflects the experience and skills required for each
      position, as well as the level of excellence demonstrated and the overall quality of the Executive’s contribution to the business. The weighting of fixed compensation within the overall package is designed to reduce the risk of excessively
      risk-oriented behavior, to discourage initiatives focused on short-term results which might jeopardize mid and long-term business sustainability and value creation, and to allow a flexible compensation approach.

    

    

    Benefits

     

    

    The Company offers to its employees benefit plans based on relevant laws and common practice in the local labor market of the Executive. In addition, in order to incentivize and reward the efforts of
      Executives on behalf of the Company, the CEO or the Compensation Committee is authorized to grant from time to time additional benefits, the value of which in each case shall not exceed NIS 3,000.

    

    

    Signing Bonus and Assistance with Relocation Expenses

      

    

    For purposes of attracting and retaining high quality personnel, the Company may offer an Executive a signing bonus as an incentive to join the Company. In addition, the Company may offer such
      Executive assistance in the form of an advance or reimbursement of relocation expenses. The signing bonus shall not exceed an amount of six months’ base salary of the Executive; the relocation advance or reimbursement may be offered on terms
      considered reasonable in the circumstances.

    

    

    Variable Compensation

     

    

    Variable compensation aims to remunerate for achievements by directly linking pay to performance outcomes in the short and long term. To strengthen the alignment of shareholder interests and the
      interests of management and employees, performance measurements reflect the actual results of the Company overall as well as of the individual Executive. As such, variable compensation constitutes a mechanism of differentiation and selectivity.
      Adequate ranges and managerial flexibility in performance-based payouts are an inherent characteristic of well-managed, accountable and sustainable variable compensation, which may be awarded via mechanisms differing by time horizon and type of
      reward.

    
      11

      
        

    

    
      
        
          
            
              
                BioLineRx Compensation Policy for Executives and Directors

              

            

          

        

      

    

     

    

    The design features, including performance measurements and payment mechanisms, must avoid an excessive short-term focus, in order to guarantee sustainable performance in the medium and long term.

    

    

    To support the aforementioned principles, the Company provides two types of variable compensation:

     

    

    
      
        	

              	•	
                Short-term - annual bonus

                 

                

              

      

    

    
      
        	

              	•	
                Long-term – equity compensation plans

              

      

    

    

    

    Short term variable compensation - annual bonus

     

    

    Annual bonuses will be based on achievement of the business goals set out in the Company’s annual operating plan approved by the Board at the beginning of each year. The operating plan encompasses
      all aspects of the Company’s activities and as such sets the business targets for each member of the management team. Consequently, the Compensation Committee and Board should be able to judge the suitability of a bonus payment by deliberating
      retrospectively at year end and comparing actual performance and target achievements against the forecasted operating plan.

    

    

    The annual bonus mechanism will be directly tied to meeting objectives - both the Company’s business objectives and the Executive’s personal objectives. The Board’s satisfaction with the Executive’s
      performance will also affect the bonus amount.

    
      12

      
        

    

    
      
        
          
            
              
                
                  BioLineRx Compensation Policy for Executives and Directors

                

              

            

          

        

      

    

     

    

    The performance metrics that will be considered are:

    

    

    	
            Metrics

          	
            Weight

          
	
            Meeting measurable clinical stage and commercial project milestones and timelines based on the Company’s operating plan, after taking into consideration the specific challenges presented by each project

          	
            30% to 40%

          
	
            Meeting measurable budget targets (at a range of 80%-110%) on an annual basis (the CEO and CFO will be measured based on the overall Company budget; while other Executives may be measured on their specific
              unit/project budgets)

          	
            20% to 30%

          
	
            Meeting measurable personal objectives based on the specific Executive’s work plan (such as cost savings, sales and marketing objectives, success in raising capital, compliance with corporate governance rules,
              project performance, etc.)

          	
            15% to 25%

          
	
            A non-material portion of the annual bonus, not in excess of 20% of the total maximum annual bonus, may be based on the Board’s satisfaction with the Executive’s performance such as:

             

            

            •          The contribution of the Executive to the Company’s business, profitability and stability

             

            

            •          The need for the Company to retain an Executive with skills, know-how, or unique expertise

             

            

            •          The responsibility imposed on the Executive

             

            

            •          Changes that occurred in the responsibility imposed on the Executive during the year

             

            

            •          Satisfaction with the Executive’s performance (including assessing the degree of involvement of the Executive and devotion of efforts in the performance

            of his/her duties)

             

            

            •          Assessing the Executive’s ability to work in coordination and cooperation with other employees of the Company

             

            

            •          The Executive’s contribution to the appropriate control and ethical environments

          	
            Up to 20%

          

    

    

    Annual bonus payments are subject to the following limitations:

     

    

    
      
        	

              	•	
                the bonus may be no more than eight monthly salaries (in the case of the CEO) or six monthly salaries (in the case of other Executives), and must correlate with a percentage of the Executive’s achieving his/her overall targets
                  (metrics);

              

         

        

        
          13

          
            

        

      

    

    
      
        
          
            
              
                
                  
                    
                      
                        BioLineRx Compensation Policy for Executives and Directors

                      

                    

                  

                

              

            

          

        

         

        

        	

              	•	
                a threshold of 50% is defined for each of the metrics, i.e., the Executive must achieve at least 50% of the target in order to be entitled to any proportional share of bonus for that target;

                 

                

              

      

    

    
      
        	

              	•	
                a weighted threshold of 50% is defined for all the metrics on a cumulative basis i.e., the Executive must achieve at least 50% of the cumulative targets in order to be entitled to a bonus;

                 

                

              

      

    

    
      
        	

              	•	
                in order to incentivize Executives to act in the best interests of the Company over the longer term, 75% of an annual bonus will be paid promptly following the date of its approval by the Board and the balance will be paid 12 months
                  following the date of its approval by the Board, on condition that (a) the Executive is still employed by the Company at the time the balance is to be paid and (b) that the Company’s financial condition still allows such bonus to be paid.

                 

                

              

      

    

    
      
        	

              	•	
                the Executive has acted in conformity with the Company’s annual operating plan as approved by the Board;

                 

                

              

      

    

    
      
        	

              	•	
                internal and external audit reports do not include significant deficiencies that were disregarded or not remedied;

                 

                

              

      

    

    
      
        	

              	•	
                there were no breaches of Company policies by the Executive.

              

      

    

    

    

    The annual bonus grant to Executives is subject to the discretion of the Compensation Committee and approval by the Board. In order to maintain some measure of flexibility, after calculating the
      compensation amount, the Board may exercise discretion about the final amount of the bonus, but may not increase the recommended bonus amount by more than 25%.

    

    

    Long-term variable compensation - equity-based compensation

     

    

    Equity-based compensation may be granted in any form permitted under the Company’s share incentive plan in effect from time to time and shall be made in accordance with the terms of such share
      incentive plan. Equity-based compensation to Executives shall be granted from time to time and be individually determined and awarded according to the performance, prior business experience, qualifications, role and the personal responsibilities of
      each Executive.

    

    

    The vesting period will generally be four years, with the vesting schedule to be determined in accordance with market compensation trends. The Company’s policy is to grant equity-based compensation
      with exercise prices at market value.

    
      14

      
        

    

    
      
        
          
            
              
                
                  
                    BioLineRx Compensation Policy for Executives and Directors

                     

                    

                  

                

              

            

          

        

      

    

    Furthermore, in order to create a ceiling for the variable compensation: (1) the aggregate value of annual grants to any one Executive (based on the Black Scholes calculation on the date of grant)
      will be no more than the higher of 2% of the Company’s market capitalization at the end of the measurement period or $1.5 million; and (2) it is the Company’s intention that the maximum outstanding equity awards under its share incentive plan will
      not exceed 12% of the Company’s total fully-diluted share capital.

    

    

    The Board may, following approval by the Compensation Committee, make provisions with respect to the acceleration of the vesting period of any Executive’s awards, including, without limitation, in
      connection with a corporate transaction involving a change of control.

    

    

    Special Bonus

     

    

    In addition to the fixed and variable compensation elements discussed above, this Policy includes the possibility of paying a special bonus to Executives on the occurrence of significant events, such
      as:

     

    

    
      
        	

              	•	
                Entering into a significant partnering transaction (payable only upon receipt of total cumulative payments of at least $7 million)

                 

                

              

      

    

    
      
        	

              	•	
                Completing a substantial funding event (not less than $15 million)

              

      

    

    

    

    When recommending a special bonus, the Compensation Committee will bring to the Board detailed arguments concerning the Executive’s entitlement to the bonus, and the Board will base its decision on
      such arguments.

    

    

    A special bonus recommended by the Compensation Committee is subject to the Board’s determination that such bonus will not have an adverse effect on the Company’s cash required to meet its operating
      plan or obligations to creditors.

    

    

    In special circumstances, and subject to the limitations detailed in this Policy, the Compensation Committee may recommend, and the Board may approve, the grant of a special bonus in order to
      maintain critical staffing necessary to implement the Company’s operating plan and/or achieve its strategic goals.

    

    

    Summary of limits for variable compensation components:

     

    

    
      
        	

              	•	
                Annual bonus - up to 8 monthly salaries, in the case of the CEO, or 6 monthly salaries, in the case of other Executives

                 

                

              

      

    

    
      
        	

              	•	
                Special bonus - up to 4 monthly salaries

              

         

        

        
          15

          
            

        

      

    

    
      
        
          BioLineRx Compensation Policy for Executives and Directors

        

         

        

        	

              	•	
                Share based compensation: (1) the aggregate value of annual grants to any one Executive (based on the Black Scholes calculation on the date of grant) will be no more than the higher of 2% of the Company’s market capitalization at the
                  end of the measurement period or $1.5 million; and (2) it is the Company’s intention that the maximum outstanding equity awards under its share incentive plan will not exceed 12% of the Company’s total fully-diluted share capital.

                 

                

              

      

    

    
      
        	

              	•	
                All bonus payments provided for in this Policy shall be payable only if the Executive is still employed by the Company at the time of payment and the Company’s financial condition allows such bonus to be paid.

              

      

    

    

    

    
      
        	

              	4.3.	
                Summary of Recommended Compensation Structure for Executives

              

      

    

     

    

    The recommended compensation structure is as follows:

    

    

    The mix of Executive compensation comprised of the various compensation elements – base salary, benefits, bonuses, stock-based compensation – should be:

    

    

    
      
        	

              	•	
                20-80% - base salary and benefits

                 

                

              

      

    

    
      
        	

              	•	
                20-80% - bonuses and stock-based compensation

              

      

    

    

    

    provided, however, that the mix may be changed for the Vice President of Business Development, taking into account the successful achievement of a significant transaction.

    The monthly salary to be paid to each Executive will not exceed:

    

    

    
      
        	

              	•	
                in the case of the Chief Executive Officer: NIS 100,000;

                 

                

              

      

    

    
      
        	

              	•	
                in the case of other Israel-based Executives: NIS 75,000; and

                 

                

              

      

    

    
      
        	

              	•	
                in the case of an Executive based in the United States, $35,000.

              

      

    

    

    

    The ratio between the total compensation package of each Executive and the average Company wage, and the ratio between the total compensation package of each Executive and the
      median Company wage will be reviewed by the Compensation Committee in order to ensure that such ratios are reasonable.

    

    

    The Company has agreed to indemnify its directors and Executives as permitted by the Companies Law. The terms of such indemnification were approved by the Board in October 2011 and, with respect to
      the directors, by the Company’s shareholders in November 2011. Indemnification on the same terms may be provided to any director or Executive whose term of office or employment, as the case may be, begins during the term of this Policy.

    
      16

      
        

    

    
      
        BioLineRx Compensation Policy for Executives and Directors

         

        

      

    

    The Company is authorized to purchase insurance policies (including run-off policies) to cover the liability of directors and Executives that are currently in office and that shall be in office from
      time to time, including directors and Executives that may have a controlling interest in the Company (if such becomes applicable in the future), within the following limits: (a) the premium for each policy period shall be not more than $550,000; (b)
      the maximum aggregate limit of liability pursuant to the policies shall be not more than $20 million for each insurance period; and (c) the maximum deductible shall be not more than $250,000. The Compensation Committee shall be authorized to increase
      the coverage purchased, and/or the premium paid for such policies, by up to 30% in any year, as compared to the previous year, or cumulatively for a number of years, without an additional shareholders’ approval to the extent permitted under the
      Companies Law.

    

    

    
      
        	

              	4.4.	
                Summary of Compensation Objectives for Executives

              

      

    

     

    

    The following is a summary of the Company’s overall compensation objectives as reflected in the compensation framework and structure described above.

     

    

    
      
        	

              	•	
                Annual performance should serve as the basis for all variable compensation:

                 

                

              

      

    

    
      
        	

              	o	
                by ensuring that bonuses correlate with the execution of the Company’s annual operating plan

                 

                

              

      

    

    
      
        	

              	o	
                by ensuring that specific business targets for each executive are communicated and updated when necessary;

                 

                

              

      

    

    
      
        	

              	o	
                by maintaining an adequate mix of quantitative operating plan goals with non-financial performance objectives (quantitative and qualitative).

                 

                

              

      

    

    
      
        	

              	•	
                Incentive systems should encourage compliance with organizational processes, behavior and conduct by mandating non-payment of bonuses in circumstances of non-compliant behavior or misconduct, as well as breach of the Company’s Code of
                  Ethics.

                 

                

              

      

    

    
      
        	

              	•	
                Consideration of risk management is an integral part of this Policy (i.e., cash flow and project mix risk assessments).

                 

                

              

      

    

    
      
        	

              	•	
                Changes in the incentive structure for all Executives may be approved by the Compensation Committee and the Board up to an immaterial amount in any one year. For purposes of this paragraph, a change of up to 8% of an Executive’s total
                  compensation in any one year will be considered immaterial and in conformance with this Policy.

              

      

    

    
      17

      
        

    

    
      
        
          BioLineRx Compensation Policy for Executives and Directors

        

         

        

        	5.	
                Compensation of Directors

              

      

    

     

    
      
        	

              	5.1.	
                Compensation of external directors (as defined in the Companies Law) will be paid in accordance with the Companies Law and applicable regulations.

              

      

    

     

    
      
        	

              	5.2.	
                Compensation of non-external directors will be identical to that of external directors.

              

      

    

     

    
      
        	

              	5.3.	
                In exceptional circumstances (e.g., a key opinion leader or globally recognized expert), the Compensation Committee and Board may approve payment of higher compensation to a director candidate, taking into consideration compliance with
                  this Policy and applicable law.

              

      

    

     

    
      
        	

              	5.4.	
                The Compensation Committee may propose, and Board may approve, the grant of equity to directors, taking into consideration compliance with this Policy and applicable law.

              

      

    

     

    
      
        	6.	
                Examination by Independent Auditors

              

      

    

     

    The calculation of Executive compensation will be reviewed annually by the Company’s independent auditor.

    

    

    
      
        	7.	
                Restitution in Case of Error

              

      

    

     

    Executives shall be required to make restitution for any payments made based on the Company’s operating performance, if such payments were based on false or restated financial statements prepared at
      any time during the three years preceding discovery of the error.

    

    

    
      
        	8.	
                Responsibility for Communication of the Policy and Revisions thereto

              

      

    

     

    The Policy, upon approval by the Board of Directors and shareholders, shall be communicated to all Executives of the Company.

    

    

    The Policy is the responsibility of the Compensation Committee, which will review it from time to time and propose to the Board that amendments be adopted as deemed necessary. Changes in the Policy
      are subject to Board and shareholder approval.

    

    

    
      
        	9.	
                Periodic Review of Executive Compensation

              

      

    

     

    The Compensation Committee and the Board will, from time to time, perform an analysis of Executive compensation and examine the relationship between each such Executive’s compensation and his/her
      contribution to Company during period following the previous analysis. In addition, the Compensation Committee and the Board will determine whether such compensation is equitable and reasonable. As a result of such analysis, changes in the
      Executive’s compensation package, as well as possible amendments to this Policy, may be considered.

    

    

    If it is decided that the compensation is not equitable and reasonable in relation to an Executive’s contribution or in relation to relevant market trends, a new discussion about his/her
      compensation package will be conducted.

    

    

    * * * * * * * *

    
      

      

      18

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00306-of-00352.parquet"}]]